Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingColorado Rocky Mountain Fetal DNA Coverage | OpenP…
    Ask Trek AI about this page
    ModifiedColorado Rocky Mountain Health PlansPolicy CS085.AH

    Cell-Free Fetal DNA Testing

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy CS085.AH alerts

    Get alerted when Policy CS085.AH changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of cell-free fetal DNA testing using maternal plasma during pregnancy, including fetal RhD genotyping and screening for selected fetal aneuploidies. It applies to providers seeking coverage for members, subject to applicable benefit, legal, and contractual requirements.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyCell-Free Fetal DNA Testing
    Policy CodePolicy CS085.AH
    Change TypeModified
    Effective DateNov 1, 2026
    Next Review DateNot specified
    Key ActionObtain genetic counseling before fetal screening or prenatal diagnosis to explain the test’s advantages and limitations.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    The applicable CPT code list was updated to reflect quarterly edits.

    CPT code 0663U was added to the applicable code list.

    2Medically necessary fetal RhD testing criteria
    3Common trisomies in screening scope
    9–10 weeksEarliest testing timing
    1Applicable CPT code added

    Coverage Criteria

    Medically Necessary Fetal RhD Testing

    Covered when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • The individual undergoing testing is alloimmunized.
      • The individual undergoing testing is at risk for alloimmunization due to maternal RhD status or the presence of red cell antigen antibodies.
    • ALL of the following

      • Paternal genotyping shows heterozygosity for RhD, or paternal RhD status is unknown.
      • Indicated invasive diagnostic testing for fetal genotyping, such as amniocentesis or chorionic villus sampling, has been offered and declined.

    Unproven and Not Medically Necessary Indications

    Cell-Free Fetal DNA testing using maternal plasma is unproven and not medically necessary for indications beyond screening for trisomies 21, 18, and 13 and sex chromosome aneuploidy. This includes, but is not limited to, the following:

    ANY of the following indications

    • Testing for the sole purpose of determining twin zygosity.
    • Genome-wide or exome-wide screening, including MaterniT Genome.
    • Expanded panel testing beyond trisomies 21, 18, and 13 and sex chromosome aneuploidy.
    • Screening for microdeletions, microduplications, or copy-number variations.
    • Screening for single-gene disorders, including Vistara or PreSeek.

    Cell-Free Fetal DNA testing using maternal plasma for the sole purpose of determining twin zygosity is unproven and not medically necessary.

    Genome-wide or exome-wide Cell-Free Fetal DNA screening, including MaterniT Genome, is unproven and not medically necessary.

    Cell-Free Fetal DNA expanded panel testing beyond trisomies 21, 18, and 13 and sex chromosome aneuploidy is unproven and not medically necessary.

    Cell-Free Fetal DNA screening for microdeletions, microduplications, copy-number variations, single-gene disorders, or fetal antigen status other than RhD is unproven and not medically necessary. Examples of single-gene disorder panels include Vistara and PreSeek.

    Cell-Free Fetal DNA testing for indications beyond screening for trisomies 21, 18, and 13 and sex chromosome aneuploidy is unproven and not medically necessary.

    Covered Indications

    Maternal-Plasma Cell-Free Fetal DNA Testing for Fetal Genotype in Alloimmunization Risk

    Coverage may be provided when all of the following are met:

    Maternal-plasma fetal genotype testing

    • The pregnant individual is alloimmunized or at risk for alloimmunization due to maternal RhD status or red cell antigen antibodies.
    • Paternal RhD status

      • Paternal genotyping shows heterozygosity for RhD.
      • Paternal RhD status is unknown.
    • Indicated invasive diagnostic testing for fetal genotyping, such as amniocentesis or chorionic villus sampling, has been offered and declined.

    Eligibility Requirements

    For high-risk single-gene noninvasive prenatal screening, a family history of a condition included on the screening panel was identified as one qualifying indication in the evaluated study. This finding does not by itself establish a general coverage requirement under this policy.

    For medically necessary fetal RhD testing, paternal genotyping must show RhD heterozygosity or the paternal RhD status must be unknown. Indicated invasive diagnostic testing, such as amniocentesis or chorionic villus sampling, must also have been offered and declined.

    Applicable Codes and Coding Criteria

    Applicable CodesCPT
    0060UTwin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood.
    0488UObstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected.
    0489UObstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (e.g., CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (e.g., cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia).
    0494URed blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative.
    0536URed blood cell antigen (fetal RhD), PCR analysis of exon 4 of RHD gene and housekeeping control gene GAPDH from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative, reported as fetal RhD status.
    0632URed blood cell antigen (fetal RhD gene analysis), multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA), plasma from pregnant individuals known to be RhD negative, reported as detected or not detected.
    0663UObstetrics (single-gene noninvasive prenatal test), cell-free DNA (cfDNA), next-generation sequencing (NGS) analysis of 1 or more targets (e.g., CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants and to determine fetal inheritance of maternal mutation, using maternal blood sample, algorithm reported as a fetal risk score.
    81479Unlisted molecular pathology procedure.
    Applicable CPT CodesCPTCovered
    0663UObstetrics (single-gene noninvasive prenatal test), cell-free DNA (cfDNA), next-generation sequencing (NGS) analysis of 1 or more targets (e.g., CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants and to determine fetal inheritance of maternal mutation, using maternal blood sample, algorithm reported as a fetal risk score.
    Nuchal translucency
    ThresholdNuchal translucency of ≥ 3.5 mm
    Paternal age indication in single-gene NIPS pilot
    ThresholdPaternal age of ≥ 40 years

    Provider Documentation and Actions

    Documentation Required

    Provide medical records for review

    Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage. Providing documentation does not guarantee coverage; coverage remains subject to federal, state, contractual, and applicable legal requirements.

    Denial Risk

    Avoid excluded or unproven indications

    Testing is considered unproven and not medically necessary when performed for indications beyond screening for trisomies 21, 18, and 13 and sex chromosome aneuploidy. This includes, but is not limited to, twin zygosity testing, genome-wide or exome-wide screening, expanded panels, microdeletions or microduplications, copy number variations, single-gene disorders, or fetal antigen status other than RhD.

    Not Covered Services

    The following are not covered because they are considered unproven and not medically necessary: twin zygosity testing performed as the sole purpose of testing; genome-wide or exome-wide screening; and expanded cell-free fetal DNA panels testing beyond trisomies 21, 18, and 13 and sex chromosome aneuploidy.

    Clinical Background

    Cell-free fetal DNA consists of placental DNA fragments circulating in the pregnant individual's blood. These fragments can be analyzed through noninvasive prenatal testing or screening, including screening for common aneuploidies as early as 9 to 10 weeks' gestation. Cell-free fetal DNA testing is a screening method and does not definitively diagnose or exclude a fetal genetic condition; chorionic villus sampling or amniocentesis is required for definitive prenatal diagnosis.

    Definitions

    Aneuploidy
    DefinitionAn abnormal number of chromosomes in a human cell, including trisomy, in which there is an extra chromosome, or monosomy, in which a chromosome is missing.
    Cell-Free Fetal DNA
    DefinitionSmall fragments of fetal DNA from the placenta that move freely in the pregnant individual's blood and can be analyzed via a noninvasive prenatal screening test.
    Comparative Genomic Hybridization
    DefinitionA technology used to detect genomic copy number variations by comparing labeled individual and reference DNA hybridized on an array.
    Noninvasive Prenatal Testing/Screening
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyCell-Free Fetal DNA Testing
    Policy CodePolicy CS085.AH
    Change TypeModified
    Effective DateNov 1, 2026
    Next Review DateNot specified
    Key ActionObtain genetic counseling before fetal screening or prenatal diagnosis to explain the test’s advantages and limitations.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsEligibility RequirementsApplicable Codes and Coding CriteriaProvider Documentation and ActionsNot Covered ServicesClinical BackgroundDefinitions
    Testing for fetal antigen status other than RhD.

    Paternal RHD genotypic analysis is recommended for RhD alloimmunization risk assessment.

    Prenatal cfDNA Screening for Fetal Trisomies 21, 18, and 13

    Prenatal cfDNA screening for fetal trisomies 21, 18, and 13 may be offered when all of the following apply:

    Common fetal aneuploidy screening

    • Gestation

      • The pregnancy is a singleton gestation.
      • The pregnancy is a twin gestation.
    • Screening is for fetal trisomies 21, 18, and 13.
    • The patient has received counseling regarding the benefits, limitations, and distinction between cfDNA screening and diagnostic testing.
    • The patient has the opportunity to accept or decline screening and diagnostic testing.

    Prenatal cfDNA Screening for Fetal Sex Chromosome Aneuploidies in Singleton Gestations

    Screening for fetal sex chromosome aneuploidies may be offered when all of the following apply:

    Singleton sex chromosome aneuploidy screening

    • The pregnancy is a singleton gestation.
    • Sex chromosome aneuploidy screening is selected as an opt-in component of cfDNA testing.
    • Appropriate pretest counseling is provided before testing.

      Counseling should address the benefits, limitations, and potential false-positive and false-negative results of screening.

    Fetal RHD Genotyping in Pregnancies at Risk for RhD Alloimmunization

    Fetal RHD genotyping may be considered when all of the following apply:

    Selected fetal RHD genotyping

    • The pregnancy is at risk for RhD alloimmunization, including an alloimmunized pregnancy with a potentially at-risk fetus.
    • Paternal RHD genotypic analysis is performed or paternal RHD status is otherwise assessed for RhD alloimmunization risk.
    • The patient declines amniocentesis or another indicated invasive diagnostic approach for fetal RHD testing.

      cfDNA testing may be used as an alternative tool in selected patients who decline amniocentesis.

    Selected Non-RhD Fetal Red Blood Cell Antigen Genotyping

    Selected non-RhD fetal red blood cell antigen genotyping may be considered when all of the following apply:

    Selected non-RhD antigen genotyping

    • The pregnant patient is being evaluated for selected non-RhD fetal red blood cell antigens.
    • The patient declines amniocentesis.
    • The patient and clinician weigh the costs and access considerations and the limited data supporting this testing.

      The available data are encouraging but limited.

    cfDNA Screening for Fetal Trisomies 21, 18, and 13

    SMFM recommends routinely offering cfDNA screening when all of the following apply:

    Routine common-trisomy screening

    • The patient is an obstetric patient who is eligible for prenatal screening.
    • Screening assesses fetal trisomies 21, 18, and 13.
    • The patient receives counseling and retains the choice to accept or decline screening and diagnostic testing.

    cfDNA Screening for Trisomy 21 in Twin Gestations

    For twin gestations, cfDNA may be used as a first-line screening option when both of the following apply:

    Trisomy 21 screening in twins

    • The pregnancy is a twin gestation.
    • Screening is for fetal trisomy 21.

      SMFM recommends cfDNA as a first-line option for trisomy 21 detection in twin gestations.

    cfDNA Screening for Trisomies 18 and 13 in Twin Gestations

    For twin gestations, cfDNA screening for trisomies 18 and 13 may be offered when both of the following apply:

    Trisomies 18 and 13 screening in twins

    • The pregnancy is a twin gestation.
    • Screening is for fetal trisomy 18 or trisomy 13.

      Screening may be offered despite limited case numbers because consistently high detection rates have been reported.

    Note

    Provide genetic counseling before testing

    Genetic counseling is strongly recommended before fetal screening or prenatal diagnosis to explain the test's advantages and limitations for the individual being tested.

    DefinitionA common term used to describe different types of analysis of cell-free fetal DNA.
    Twin Zygosity
    DefinitionThe type of conception: dizygotic twins result from fertilization of two separate ova by two separate sperm cells and share approximately 50% of genes, while monozygotic twins result from division of a zygote formed by one ovum and one sperm cell.
    Whole-Genome Sequencing
    DefinitionSequencing the entire DNA sequence in a person or tissue, including coding and noncoding DNA elements.
    Confined placental mosaicism
    DefinitionThe presence of genetically abnormal cells in the placenta that are not necessarily present in the fetus; it is a frequent explanation for positive cfDNA results that are not confirmed in the fetus.
    Rare autosomal aneuploidies
    DefinitionChromosomal abnormalities involving autosomes other than the commonly screened trisomies 13, 18, and 21.
    No-call result
    DefinitionA cfDNA screening result that is not reported by the laboratory or is uninterpretable; a no-call result is associated with increased aneuploidy risk.
    Fetal fraction
    DefinitionThe proportion or amount of fetal DNA available in the maternal cfDNA sample; insufficient fetal fraction is the most frequent explanation for a no-call result.
    GRADE 1A
    DefinitionStrong recommendation based on high-quality evidence.
    GRADE 1B
    DefinitionStrong recommendation based on moderate-quality evidence.
    GRADE 1C
    DefinitionStrong recommendation based on low-quality evidence.